Sellas Life Sciences Shares Surge After Leukemia Vaccine Shows Survival Benefit
Sellas Life Sciences' stock surged 156% in one day after its experimental leukemia vaccine, galinpepimut-S (GPS), significantly extended survival in a late-stage Phase 3 trial. The vaccine reduced death risk by 41%, with median survival reaching 24 months compared to 14.7 months for standard treatment in acute myeloid leukemia patients. The company plans to discuss accelerated FDA approval, targeting a 2027 filing. The stock rose further by 5% following the initial surge, reflecting investor optimism about the treatment's potential.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 44/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (85–85/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 18 Nov, 06:41 am. Other outlets followed.
